

Supplementary Table 3. Baseline characteristics of patients with liver cirrhosis grouped according to the COVID-19 infection before case-control matching (n = 13,681)

Characteristic	LC+ COVID+ (n = 67)	LC+ COVID− (n = 6,395)	LC− COVID+ (n = 7,219)	p value
Male sex ^a	40 (59.7)	4,076 (63.7)	2,896 (40.1)	< 0.01
Age, yr ^{a,b}	59.9 ± 15.7	62.3 ± 14.3	47.2 ± 18.9	< 0.01
Region of diagnosis				
Daegu & Gyeongbuk ^a	43 (64.2)	770 (12.0)	3,865 (53.5)	< 0.01
Tested hospital				
3rd ^a	9 (13.4)	3,300 (51.6)	1,389 (19.2)	< 0.01
Comorbidities				
Decompensated liver cirrhosis ^{a,b}	19 (28.4)	3,199 (50.0)	0	< 0.01
Diabetes ^a	21 (31.3)	2,488 (38.9)	802 (11.1)	< 0.01
Hypertension ^{a,b}	27 (40.3)	3,645 (57.0)	1,714 (23.7)	< 0.01
Dyslipidemia	19 (28.4)	2,329 (36.4)	1,584 (21.9)	< 0.01
Cardiovascular disease	9 (13.4)	1,393 (21.8)	540 (7.5)	< 0.01
Cancer ^{a,b}	12 (17.9)	3,022 (47.3)	330 (4.6)	< 0.01
COPD ^a	9 (13.4)	1,763 (27.6)	726 (10.1)	< 0.01
Asthma	12 (17.9)	1,472 (23.0)	915 (12.7)	< 0.01
ESRD with dialysis ^a	0	387 (6.1)	20 (0.3)	< 0.01
Immunocompromised status ^a	9 (13.4)	480 (7.5)	265 (3.7)	< 0.01
CCI ^{a,b}	4.3 ± 2.7	6.8 ± 3.8	1.4 ± 1.9	< 0.01
Severe complications ^{a,b}	18 (26.9)	1,068 (16.7)	686 (9.5)	< 0.01
Oxygen therapy ^{a,b}	12 (17.9)	631 (9.9)	574 (7.8)	< 0.01
Vasopressors ^a	4 (6.0)	267 (4.2)	97 (1.3)	< 0.01
Admission for intensive care unit	2 (3.0)	252 (3.9)	110 (1.5)	< 0.01
Continuous renal replacement therapy	1 (1.5)	44 (0.7)	21 (0.3)	< 0.01
Death ^a	6 (9.0)	501 (7.8)	225 (3.1)	< 0.01
Liver cirrhosis related complications				
Varix	3 (4.5)	524 (8.2)	-	0.37
Ascites	2 (3.0)	195 (3.1)	-	1.00
Hepatorenal syndrome	2 (3.0)	350 (5.5)	-	0.59
Spontaneous bacterial peritonitis	0	64 (1.0)	-	1.00
Encephalopathy	3 (4.5)	11 (0.2)	-	0.74

Values are presented as number (%) or mean ± standard deviation.

COVID-19, coronavirus disease 2019; LC, liver cirrhosis; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; CCI, Charlson comorbidity index.

^ap < 0.05 between LC+ COVID+ and LC− COVID+.

^bp < 0.05 between LC+ COVID+ and LC+ COVID−.